Is there an Increased Risk of Central Nervous System Metastasis in Cases with Gastric Cancer Showing Her2 Expression and Treated by Trastuzumab?
|Department of Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey|
|Corresponding Author :||Semra Paydas
Department of Oncology
Faculty of Medicine
Cukurova University, Adana, Turkey
E-mail: [email protected]
|Received August 19, 2013; Accepted Septeber 20, 2013; Published September 22, 2013|
|Citation: Paydas S (2013) Is there an Increased Risk of Central Nervous System Metastasis in Cases with Gastric Cancer Showing Her2 Expression and Treated by Trastuzumab? J Clin Case Rep 3:299. doi:10.4172/2165-7920.1000299|
|Copyright: © 2013 Paydas S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
The oncogene encoding Her2 receptor which has an important biologic significance in human cancers has been described 30 years ago by Schecter et al. Her2 amplification in gastric cancer has been shown in MKN-7 gastric cancer cell line firstly by Fukushige et al. in 1986. Later studies showed variable expression of ERBB2 in gastric cancer and Her2 expression rate has been found between 8% and 54%. Significant survival advantage has been reported with the introduction of trastuzumab in cases with gastric cancer expressing ERBB2. Other anti-ERBB2 agents are used in ongoing studies and longer survival times are expected. By analogy with ERBB2 breast cancer it can be speculated that central nervous system metastases may increase in these cases with increased survival times. Here we reported brain metastases in a case with metastatic gastric cancer treated by trastuzumab containing regimen.